Executive Summary
Three new federal contracts totaling $1,236,299,978 in obligations, with 1/3 defense-related, highlight civilian agency IT and construction spending via GSA, VA, and Department of State awards to Leidos, Inc. ($543.6M), Oracle Health Government Services, Inc. ($519.0M), and BL Harbert International LLC ($173.7M). Dominant theme is mature civilian IT delivery orders with significant backlog but zero or negative outlays to date.
Highest-conviction bullish signal is Oracle's $519M VA EHRM operations contract (materiality 8/10, strength 7/10), signaling stable multi-year revenue in VA IT services. Key risk is high pricing risk on firm-fixed-price structures for Oracle and BL Harbert, compounded by unexercised options and $0 outlays across all contracts. Watch outlay progress and option exercises through 2027 end dates.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from April 10, 2026.
Investment Signals (4)
- Leidos, Inc. Secures $543.6M GSA IT Delivery Order (MEDIUM)▲
Leidos, Inc. received a $543,645,833 obligation (potential $729.6M with options) under cost-plus award fee from GSA for IT and telecom services, representing ~$83.6M annual revenue estimate over 6.5 years despite negative $1.7M outlay.
- Oracle Health Government Services Wins $519.0M VA EHRM Contract (HIGH)▲
Oracle Health Government Services, Inc. awarded $518,959,505 obligation (potential $632.8M with options) firm-fixed-price delivery order from VA for EHRM operations, equating to ~$104M annual revenue over 5 years with $0 outlay to date.
- BL Harbert International LLC Awarded $173.7M State Department Construction Contract (LOW)▲
BL Harbert International LLC received $173,694,639 firm-fixed-price contract from Department of State for Podgorica Montenegro project, ~$23.1M annual over 7.5 years with $0 outlay and $5.5M subawards.
- Zero Outlays Across $1.2B Obligations Signal Execution Delays (HIGH)▲
All three contracts show $0 or negative outlays (Leidos -$1.7M, Oracle $0, BL Harbert $0), raising near-term cash flow risks despite high obligations.
Risk Flags (2)
- Execution [HIGH RISK]▼
Leidos GSA contract nears 2024-02-29 end with negative -$1.7M outlay and uncertain option exercise to $729.6M.
- Budget [HIGH RISK]▼
Oracle VA and BL Harbert State contracts at high pricing risk under firm-fixed-price with $0 outlays and unexercised options to $632.8M and matching obligation.
Opportunities (2)
- ◆
Leidos GSA IT order offers upside to $729.6M via remaining options in cost-plus structure with 1090 subawards.
- ◆
Oracle VA EHRM contract potential to $632.8M with first outlays from current $0.
Sector Themes (1)
- ◆
Leidos ($543.6M GSA) and Oracle ($519.0M VA) delivery orders under NAICS 541512 total over $1B in obligations for IT systems and EHRM, with cost-plus and firm-fixed structures but $0/negative outlays.
Watch List (3)
- 👁
{"entity"=>"Leidos Holdings, Inc. (LDOS)", "reason"=>"GSA contract total outlay progress from -$1.7M and options to $729.6M through 2024-02-29 end.", "trigger"=>"outlay updates, option exercise"}
- 👁
{"entity"=>"Oracle Corporation (ORCL)", "reason"=>"VA EHRM outlay from $0 and options to $632.8M through 2027-04-10.", "trigger"=>"outlay initiation, option exercise"}
- 👁
{"entity"=>"BL Harbert International LLC", "reason"=>"State Department outlay from $0 and performance to 2027-03-25.", "trigger"=>"outlay progress"}
Get daily alerts with 4 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals